	US 11,746,140 B2
	Composition comprising recombinant GPlbα receptor protein
Elizabeth Booth, Berkeley, CA (US); Virginia Montanini, L'Ametlla del Valles (ES); John A. Hall, Rohnert Park, CA (US); and Jody Berry, Easton, PA (US)
Assigned to F. HOFFMAN-LA ROCHE AG, Basel (CH)
Appl. No. 16/479,068
Filed by Grifols Diagnostic Solutions Inc., Emeryville, CA (US)
PCT Filed Feb. 15, 2019, PCT No. PCT/IB2019/051227 § 371(c)(1), (2) Date Jul. 18, 2019, PCT Pub. No. WO2019/162813, PCT Pub. Date Aug. 29, 2019.
Claims priority of provisional application 62/632,870, filed on Feb. 20, 2018.
Prior Publication US 2022/0033473 A1, Feb. 3, 2022
Int. Cl. C07K 14/705 (2006.01); C07K 14/745 (2006.01)

CPC C07K 14/745 (2013.01) [C07K 14/705 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01)]

26 Claims

1. A recombinant polypeptide that specifically binds human von Willebrand Factor, comprising a modified extracellular domain of platelet glycoprotein Ibα wherein:

the recombinant polypeptide lacks a transmembrane domain; and

the modified extracellular domain comprises at least one mutation selected from G233T, D235V, and K237V, relative to SEQ ID NO: 19,

wherein the modified extracellular domain comprises at least 250 consecutive amino acids of an amino acid sequence selected from the group consisting of: SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; and SEQ ID NO: 5.